文献速递心律失常心力衰竭与心肌病

循环I型胶原相关生物标志物组合与心房颤动相关

Combination of Circulating Type I Collagen-Related Biomarkers Is Associated With Atrial Fibrillation.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

在242例心衰患者和150例房颤消融患者中,评估反映心肌I型胶原过度交联(CCL+)和沉积(CD+)的循环标志物组合与房颤的关系。CCL+CD+组合与基线房颤、新发房颤及消融后复发风险升高相关,且提供增量预测价值,并与左房电压降低相关。

要点

  • CCL+CD+生物标志物组合与心衰患者基线房颤和随访中新发房颤风险升高相关。
  • 在房颤消融患者中,CCL+CD+组合与消融后1年房颤复发风险升高相关。
  • CCL+CD+患者左心房电压较低,提示该组合可能反映心房基质异常。

核心结论

  • 反映心肌I型胶原过度交联和沉积的循环生物标志物组合与房颤患病率、发病率及消融后复发率升高相关。

研究设计与样本

  • 研究1纳入242例心衰患者,研究2纳入150例转诊行房颤消融的患者,分析血清生物标志物。
  • 根据生物标志物阈值将患者分为CCL-CD-、CCL+CD-或CCL-CD+、CCL+CD+三组。
  • 研究2中对71例患者进行了左心房电解剖高密度标测。

主要发现

  • 研究1中基线房颤患病率为53.7%,中位随访5.5年期间19.6%患者新发房颤。
  • 研究1中,与CCL-CD-患者相比,CCL+CD+患者基线房颤的校正比值比和新发房颤的校正风险比均≥3.3(p≤0.050),其他组无显著变化。
  • 研究2中消融后1年房颤复发率为29.3%;与CCL-CD-患者相比,CCL+CD+患者房颤复发的校正风险比为3.4(p=0.008),其他组无显著变化。
  • CCL+CD+组合在相关协变量之上提供增量预测价值。
  • CCL+CD+患者左心房电压低于其余患者(p=0.005)。

关键数值与推荐

  • CCL+定义为I型胶原羧基末端端肽与基质金属蛋白酶-1比值降低。
  • CD+定义为I型前胶原羧基末端前肽升高。

临床怎么用

  • 循环I型胶原相关生物标志物组合(CCL+CD+)可能有助于识别房颤高风险或消融后复发风险较高的心衰患者。
  • 该组合与左心房电压降低相关,或可提示心房基质异常,但尚需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A combination of circulating biomarkers associated with excessive myocardial collagen type-I cross-linking or CCL+ (i.e., decreased carboxy-terminal telopeptide of collagen type-I to matrix metalloproteinase-1 ratio) and with excessive myocardial collagen type-I deposition or CD+ (i.e., increased carboxy-terminal propeptide of procollagen type-I) has been described in heart failure (HF) patients and associates with poor outcomes. OBJECTIVES: The purpose of this study was to investigate whether the CCL+CD+ combination of biomarkers associates with atrial fibrillation (AF). METHODS: Biomarkers were analyzed in serum samples from 242 HF patients (study 1) and 150 patients referred for AF ablation (study 2). Patients were classified into 3 groups (CCL-CD-, CCL+CD- or CCL-CD+, and CCL+CD+) in accordance to biomarker threshold values. Left atrial electroanatomic high-density mapping was performed in 71 patients from study 2. RESULTS: In study 1, 53.7% patients had AF at baseline and 19.6% developed AF (median follow-up 5.5 years). Adjusted odds and hazard ratios associated with baseline and new-onset AF, respectively, were both ≥3.3 (p ≤ 0.050) in CCL+CD+ patients compared with CCL-CD- patients, with nonsignificant changes in the other group. In study 2, 29.3% patients had AF recurrence during 1-year post-ablation. The adjusted hazard ratio for AF recurrence was 3.4 (p = 0.008) in CCL+CD+ patients compared with CCL-CD- patients, with nonsignificant changes in the other group. The CCL+CD+ combination added incremental predictive value over relevant covariables. CCL+CD+ patients exhibited lower left atrial voltage than the remaining patients (p = 0.005). CONCLUSIONS: A combination of circulating biomarkers reflecting excessive myocardial collagen type-I cross-linking and deposition is associated with higher AF prevalence, incidence, and recurrence after ablation.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Ravassa S, Ballesteros G, López B, et al. Combination of Circulating Type I Collagen-Related Biomarkers Is Associated With Atrial Fibrillation. J Am Coll Cardiol. 2019. PMID: 30922470. doi:10.1016/j.jacc.2018.12.074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。